$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

OACC

Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC)

$10.43

Delayed price

Profit since last BUY0.29%

Consider higher Upturn Star rating

BUY since 20 days

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

05/27/2025: OACC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock

Historic Profit 0.59%

Avg. Invested days 28

Today’s Advisory Consider higher Upturn Star rating

Upturn Star Rating

Upturn Advisory Performance

5.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 05/27/2025

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 256.64M USD	Price to earnings Ratio -	1Y Target Price -
Price to earnings Ratio -	1Y Target Price -
Volume (30-day avg) 133160	Beta -	52 Weeks Range 9.95 - 10.85	Updated Date 05/30/2025
52 Weeks Range 9.95 - 10.85	Updated Date 05/30/2025
Dividends yield (FY) -	Basic EPS (TTM) -

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -	Enterprise Value 255374438	Price to Sales(TTM) -
Enterprise Value 255374438	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 19783000	Shares Floating 17802841
Shares Outstanding 19783000	Shares Floating 17802841
Percent Insiders -	Percent Institutions 80.42

Analyst Ratings

Rating -	Target Price -	Buy -	Strong Buy -
Buy -	Strong Buy -
Hold -	Sell -	Strong Sell -
Strong Sell -

About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share

Exchange NASDAQ	Headquaters Los Angeles, CA, United States
IPO Launch date 2024-12-16	CEO & Director Mr. Zaid Pardesi
Sector Financial Services	Industry Shell Companies	Full time employees -	Website https://www.oaktreeacquisitioncorp.com/oac-iii
Full time employees -	Website https://www.oaktreeacquisitioncorp.com/oac-iii

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.